ArticleInfection and immunity2003
Analysis of virulence and inflammatory potential of Shigella flexneri purine biosynthesis mutants.
Article in Infection and immunity, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- Probiotic supplementation promotes a reduction in T-cell activation, an increase in Th17 frequencies, and a recovery of intestinal epithelium integrity and mitochondrial morphology in ART-treated HIV-1-positive patients.Immunity, inflammation and disease · 2017Trial
- Construction, molecular characterization, and safety assessment ofFrontiers in microbiology · 2024Article
- Systematic inference identifies a major source of heterogeneity in cell signaling dynamics: The rate-limiting step number.Science advances · 2022Article
- Pharmacological modulation of mitochondrial calcium uniporter controls lung inflammation in cystic fibrosis.Science advances · 2020Article
- Artificial Selection for Pathogenicity Mutations inInfection and immunity · 2019Article
- Role of a fluid-phase PRR in fighting an intracellular pathogen: PTX3 in Shigella infection.PLoS pathogens · 2018Article
- IL-17A impairs host tolerance during airway chronic infection by Pseudomonas aeruginosa.Scientific reports · 2016Article
- Article
- Protective Enterotoxigenic Escherichia coli Antigens in a Murine Intranasal Challenge Model.PLoS neglected tropical diseases · 2015Article
- Preferential use of central metabolism in vivo reveals a nutritional basis for polymicrobial infection.PLoS pathogens · 2015Article
- Structural and biochemical characterization of N5-carboxyaminoimidazole ribonucleotide synthetase and N5-carboxyaminoimidazole ribonucleotide mutase from Staphylococcus aureus.Acta crystallographica. Section D, Biological crystallography · 2011Article
- Shigella enterotoxin-2 is a type III effector that participates in Shigella-induced interleukin 8 secretion by epithelial cells.FEMS immunology and medical microbiology · 2011Article
- Emergence of a novel Shigella flexneri serotype 4s strain that evolved from a serotype X variant in China.Journal of clinical microbiology · 2011Article
- A Burkholderia pseudomallei deltapurM mutant is avirulent in immunocompetent and immunodeficient animals: candidate strain for exclusion from select-agent lists.Infection and immunity · 2010Article
- Carbon metabolism of intracellular bacterial pathogens and possible links to virulence.Nature reviews. Microbiology · 2010Review
- Carbon metabolism of enterobacterial human pathogens growing in epithelial colorectal adenocarcinoma (Caco-2) cells.PloS one · 2010Article
- Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants.Infection and immunity · 2010Article
- Life on the inside: the intracellular lifestyle of cytosolic bacteria.Nature reviews. Microbiology · 2009Review
- Identification of inhibitors of N5-carboxyaminoimidazole ribonucleotide synthetase by high-throughput screening.Bioorganic & medicinal chemistry · 2009Article
- The critical role of the linear plasmid lp36 in the infectious cycle of Borrelia burgdorferi.Molecular microbiology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several Shigella flexneri mutants with defects in aromatic amino acid and/or purine biosynthesis have been evaluated as vaccines in humans or in animal models. To be suitable as a vaccine, a mutant has to show virulence attenuation, minimal reactogenicity, and a good immunogenic potential in animal models. With this aim, we have constructed five S. flexneri 5 (wild-type strain M90T) mutants with inactivation of one or two of the loci purEK, purHD, and guaBA, governing early or late steps of purine biosynthesis. The mutants have been analyzed in vitro in cell cultures and in vivo in the Sereny test and in the murine pulmonary model of shigellosis. M90T guaBA, M90T guaBA purEK, M90T guaBA purHD, and M90T purHD purEK gave a negative result in the Sereny test. In contrast, in the murine pulmonary model all of the strains had the same 50% lethal dose as the wild type, except M90T guaBA purHD, which did not result in death of the animals. Nevertheless, bacterial counts in infected lungs, immunohistochemistry, and reverse transcription-PCR analysis of mRNAs for tumor necrosis factor alpha (TNF-alpha), gamma interferon (IFN-gamma), interleukin-1beta (IL-1beta), IL-6, IL-12, and inducible nitric oxide synthase (iNOS) revealed significant differences among the strains. At 72 h postinfection, M90T guaBA purHD still induced proinflammatory cytokines and factors such as IL-1beta, IL-6, TNF-alpha, and iNOS, along with cytokines such as IL-12 and IFN-gamma. Moreover, in the absence of evident lesions in murine tissues, this mutant highly stimulated major histocompatibility complex class II expression, showing a significant ability to activate the innate immunity of the host.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.